Shaperon CI. /Courtesy of the company

Shaperon successfully completed part 1 of the multinational phase 2 clinical trial of 'HY209 gel' targeting patients with mild to moderate atopic dermatitis and has received approval to proceed with part 2 of the clinical trial, leading to a strong stock price in the early trading on the 14th.

As of 9:15 a.m. on that day, Shaperon was trading at 4,940 won, an increase of 690 won (16.24%) from the previous trading day.

Before the market opened that day, Shaperon announced that the independent 'Safety Monitoring Committee (SMC)' evaluated the clinical results of the phase 2b part 1 clinical trial of the atopic dermatitis treatment 'Nugel' according to U.S. Food and Drug Administration (FDA) regulatory guidelines and received a recommendation from the SMC to continue with the subsequent phase 2b part 2 trial.

Based on this recommendation from the SMC, Shaperon plans to conduct part 2 of the clinical trial involving 177 patients of various ethnicities across a total of 12 hospitals, adding 4 additional hospitals each in the U.S. and Korea to the existing 4.

The company noted that part 1 of the clinical trial confirmed that Nugel is safe even when administered at high doses over a long period and that positive results were also observed in terms of efficacy, indicating a very high likelihood of success in the follow-up part 2 clinical trial.